AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11458140 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency articular facet denervation under fluoroscopic guidance
Number of subjects: 70
Study 11458140 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (same procedure without effective denervation)
Number of subjects: 70
Study 8420421 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ICI 204,219 orally
Number of subjects: 8
Study 8420421 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8
Study 3535695 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of 0.9% saline containing 1.5 mg PGE2
Number of subjects: 30
Study 3535695 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of 0.9% saline (placebo)
Number of subjects: 30
Study 28965369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Bilateral Balanced Occlusion (FBBO)
Number of subjects: 86
Study 28965369 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccalised Occlusion (BO)
Number of subjects: 86
Study 28965369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualised Occlusion (LO)
Number of subjects: 86
Study 28965369 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for patient satisfaction
Number of subjects: 86
Study 28965369 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for prosthodontist satisfaction
Number of subjects: 86
Study 27573605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 20
Study 27573605 — intervention group
Group type: COMPARATOR
Intervention: Control (glimepiride)
Number of subjects: 20
Study 26508131 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 91
Study 26508131 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 91
Study 24441085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby music
Number of subjects: 25
Study 24441085 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 25
Study 24441085 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 25
Study 21419317 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rice lees (LB)
Number of subjects: 30
Study 21419317 — intervention group
Group type: COMPARATOR
Intervention: Mixed-grain dietary product (MG)
Number of subjects: 30
Study 18003765 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hemodialysis
Number of subjects: 4
Study 18003765 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback dialysis
Number of subjects: 4
Study 16517534 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (80 mg/kg every 6 h, max 4.5 g/dose)
Number of subjects: 27
Study 16517534 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (50 mg/kg every 8 h, max 2 g/dose)
Number of subjects: 27
Study 16517534 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 27
Study 16517534 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 27
Study 16517534 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam and Cefepime
Number of subjects: 27
Study 14680045 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mile run
Number of subjects: 44
Study 14680045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 11000319 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations placed using cotton rolls and aspiration isolation
Number of subjects: 100
Study 11000319 — intervention group
Group type: COMPARATOR
Intervention: Restorations placed using rubber dam isolation
Number of subjects: 100
Study 9148225 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 86
Study 9148225 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 86
Study 1601598 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation with planned physical therapy
Number of subjects: 0
Study 1601598 — intervention group
Group type: COMPARATOR
Intervention: Hospital rehabilitation
Number of subjects: 0
Study 3547214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol therapy
Number of subjects: 38
Study 3547214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no betamimetic agents)
Number of subjects: 38
Study 29766301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures reinforced with non-absorbable mesh
Number of subjects: 72
Study 29766301 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 72
Study 29766301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 27739087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic infusion of hypertonic saline into the right anterior temporalis muscle
Number of subjects: 14
Study 27739087 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 14
Study 27739087 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline infusion
Number of subjects: 14
Study 25721866 — intervention group
Group type: EXPERIMENTAL
Intervention: OM‐89S (6 mg daily for 10 days, placebo for 20 days)
Number of subjects: 451
Study 25721866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 25721866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg daily for 30 days)
Number of subjects: 451
Study 23889885 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel ointment (T-O)
Number of subjects: 449
Study 23889885 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel gel (T-G)
Number of subjects: 449
Study 23889885 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac gel (D-G)
Number of subjects: 449
Study 23889885 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel ointment (T-O) and Traumeel gel (T-G)
Number of subjects: 449
Study 23889885 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 449
Study 21078416 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in CSP 474
Number of subjects: 0
Study 21078416 — intervention group
Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 0
Study 21078416 — intervention group
Group type: EXPERIMENTAL
Intervention: Participating sites
Number of subjects: 0
Study 21078416 — intervention group
Group type: COMPARATOR
Intervention: Non-participating sites
Number of subjects: 0
Study 20234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.2 mg/kg/day
Number of subjects: 226
Study 20234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 2.4 mg/kg/day
Number of subjects: 226
Study 20234828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 16728291 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 13 and n = 14)
Number of subjects: 53
Study 16728291 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12 and n = 14)
Number of subjects: 53
Study 14966096 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular completion of HRQL questionnaires and feedback to physicians
Number of subjects: 286
Study 14966096 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (completion of questionnaires, but no feedback)
Number of subjects: 286
Study 14966096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRQL measurement in clinic before encounters)
Number of subjects: 286
Study 14966096 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of HRQL data
Number of subjects: 286
Study 14966096 — intervention group
Group type: COMPARATOR
Intervention: Instrument completion without feedback
Number of subjects: 286
Study 14966096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 286
Study 14966096 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit use of HRQL data in intervention group
Number of subjects: 286
Study 14966096 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient management
Number of subjects: 286
Study 11421997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg single dose
Number of subjects: 36
Study 11421997 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade B)
Number of subjects: 36
Study 11421997 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade C)
Number of subjects: 36
Study 9014993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 8 micrograms/kg
Number of subjects: 91
Study 9014993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 4 micrograms/kg
Number of subjects: 91
Study 9014993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 9014993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (both doses)
Number of subjects: 91
Study 8344127 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg.kg‐1.day‐1 for 10 days, then 0.3 mg.kg‐1.day‐1 for 50 days)
Number of subjects: 32
Study 8344127 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 32
Study 8344127 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 3526590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 30
Study 3526590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31465849 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular decompression (MVD) for hemifacial spasm (HFS)
Number of subjects: 636
Study 31465849 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 patients without DFP)
Number of subjects: 636
Study 29538662 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual gain-framed messages
Number of subjects: 402
Study 29538662 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual loss-framed messages
Number of subjects: 402
Study 29538662 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional gain-framed messages
Number of subjects: 402
Study 29538662 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional loss-framed messages
Number of subjects: 402
Study 27567243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glyburide
Number of subjects: 86
Study 27567243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 24448992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 396
Study 24448992 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 396
Study 22113063 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Aspartate transaminase (AST)
Number of subjects: 1783
Study 22113063 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Alanine transaminase (ALT)
Number of subjects: 1783
Study 20045564 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg retina tomograph (HRT) Glaucoma Probability Score (GPS)
Number of subjects: 198
Study 20045564 — intervention group
Group type: COMPARATOR
Intervention: Visual field (VF) assessment
Number of subjects: 198
Study 18938672 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion
Number of subjects: 24
Study 18938672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15811647 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based lecture on the benefits of the polio vaccine
Number of subjects: 97
Study 15811647 — intervention group
Group type: COMPARATOR
Intervention: Presentation from a visibly affected victim of polio
Number of subjects: 97
Study 15811647 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based lecture
Number of subjects: 97
Study 12575962 — intervention group
Group type: COMPARATOR
Intervention: cTnT-negative patients with no ST
Number of subjects: 959
Study 12575962 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT-positive patients with ST ≥2 mm
Number of subjects: 959
Study 12575962 — intervention group
Group type: EXPERIMENTAL
Intervention: ST ≥2 mm on ECGs done after 6 h of symptom onset
Number of subjects: 959
Study 12575962 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cTnT within 6 h of symptom
Number of subjects: 959
Study 10587936 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Abbreviated treatment
Number of subjects: 412
Study 10587936 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 412
Study 10587936 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month course of treatment (including at least 6 months in a therapeutic community followed by outpatient treatment)
Number of subjects: 412
Study 8916874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini repair
Number of subjects: 315
Study 8916874 — intervention group
Group type: EXPERIMENTAL
Intervention: McVay repair
Number of subjects: 315
Study 8916874 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 315
Study 1885899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study 1885899 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 6859420 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendectomy
Number of subjects: 184
Study 6859420 — intervention group
Group type: EXPERIMENTAL
Intervention: No easy appendectomy
Number of subjects: 184
Study 6859420 — intervention group
Group type: COMPARATOR
Intervention: Control (no appendectomy)
Number of subjects: 184
Study 31957654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months, including once weekly 90-minute in-facility exercise sessions and 4 days per week at-home exercise sessions.
Number of subjects: 15
Study 31957654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months.
Number of subjects: 15
Study 30803386 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency Transposition (FT)
Number of subjects: 10
Study 30803386 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency Compression (FC)
Number of subjects: 10
Study 30803386 — intervention group
Group type: COMPARATOR
Intervention: Control (no frequency lowering)
Number of subjects: 10
Study 28144724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal naloxone 0.8 mg
Number of subjects: 12
Study 28144724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal naloxone 1.6 mg
Number of subjects: 12
Study 28144724 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone 1.0 mg
Number of subjects: 12
Study 26750736 — intervention group
Group type: EXPERIMENTAL
Intervention: CSI-CY (experimental group)
Number of subjects: 61
Study 26750736 — intervention group
Group type: COMPARATOR
Intervention: Control group (current IEP)
Number of subjects: 61
Study 25086209 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants led to believe their food consumption was being recorded
Number of subjects: 0
Study 25086209 — intervention group
Group type: COMPARATOR
Intervention: Participants' beliefs about their eating behaviour being monitored
Number of subjects: 0
Study 22002479 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX) for 7 days
Number of subjects: 40
Study 22002479 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 40
Study 22002479 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 7 days (given if B hominis was still present)
Number of subjects: 40
Study 22002479 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous clearance (no treatment)
Number of subjects: 40
Study 22002479 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX)
Number of subjects: 40
Study 22002479 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 40
Study 19280185 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 23
Study 19280185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17127224 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg administered as a single dose in a 1 hour infusion (250 ml) for perioperative prophylaxis
Number of subjects: 39
Study 14985524 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling (7 consultations over 9 months)
Number of subjects: 299
Study 14985524 — intervention group
Group type: COMPARATOR
Intervention: Control group (received written information on lifestyle factors)
Number of subjects: 299
Study 14985524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 299
Study 11729380 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 724
Study 11729380 — intervention group
Group type: COMPARATOR
Intervention: Mini-laparotomy cholecystectomy (MC)
Number of subjects: 724
Study 9388809 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer collaborative activity with higher metacognitive understanding children
Number of subjects: 0
Study 9388809 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group membership (collaborative recall task)
Number of subjects: 0
Study 7639364 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 39
Study 7639364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3203179 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent token reinforcement intervention
Number of subjects: 1
Study 3203179 — intervention group
Group type: COMPARATOR
Intervention: Goal-setting plus extinction procedure
Number of subjects: 1
Study 31240723 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus MOL
Number of subjects: 36
Study 31240723 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 36
Study 28830881 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation (DE)
Number of subjects: 0
Study 28830881 — intervention group
Group type: COMPARATOR
Intervention: Control group (current dose for the first 12 months)
Number of subjects: 0
Study 28830881 — intervention group
Group type: COMPARATOR
Intervention: Both groups (DE and control)
Number of subjects: 0
Study 26397083 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training (BWSTT)
Number of subjects: 24
Study 26397083 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued physical therapy)
Number of subjects: 24
Study 23357640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud therapy (11 consecutive sessions of peloids applied to the knee)
Number of subjects: 147
Study 23357640 — intervention group
Group type: COMPARATOR
Intervention: Routine drug treatment (Control group)
Number of subjects: 147
Study 22035459 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy with cetuximab
Number of subjects: 420
Study 22035459 — intervention group
Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy without cetuximab (control)
Number of subjects: 420
Study 19021289 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label use of vascular devices
Number of subjects: 0
Study 19021289 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with alternative devices
Number of subjects: 0
Study 15191269 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfectionism
Number of subjects: 121
Study 15191269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias
Number of subjects: 121
Study 15191269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 121
Study 15191269 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient depression and suicidal ideation severity
Number of subjects: 121
Study 11952546 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Symptom Management Programme (PSMP)
Number of subjects: 93
Study 11952546 — intervention group
Group type: COMPARATOR
Intervention: Standard psoriasis treatment alone
Number of subjects: 93
Study 9846680 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI followed by timed intercourse
Number of subjects: 201
Study 9846680 — intervention group
Group type: COMPARATOR
Intervention: IUI alone
Number of subjects: 201
Study 8205404 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax baths plus pulsed ultrasound (short-term application)
Number of subjects: 0
Study 8205404 — intervention group
Group type: COMPARATOR
Intervention: Wax baths (short-term application)
Number of subjects: 0
Study 8205404 — intervention group
Group type: COMPARATOR
Intervention: Pulsed ultrasound alone (short-term application)
Number of subjects: 0
Study 8205404 — intervention group
Group type: COMPARATOR
Intervention: Exercise (short-term application)
Number of subjects: 0
Study 8205404 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax baths plus pulsed ultrasound (long-term application)
Number of subjects: 0
Study 8205404 — intervention group
Group type: COMPARATOR
Intervention: Wax baths (long-term application)
Number of subjects: 0
Study 8205404 — intervention group
Group type: COMPARATOR
Intervention: Pulsed ultrasound alone (long-term application)
Number of subjects: 0
Study 8205404 — intervention group
Group type: COMPARATOR
Intervention: Exercise (long-term application)
Number of subjects: 0
Study 2572189 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 41
Study 2572189 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 41
Study 1105489 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 1105489 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study 1105489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30658546 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 281
Study 30658546 — intervention group
Group type: COMPARATOR
Intervention: Manualised treatment
Number of subjects: 281
Study 29262824 — intervention group
Group type: EXPERIMENTAL
Intervention: Active manipulation of the sphenopalatine ganglion (SPG)
Number of subjects: 10
Study 29262824 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation of the sphenopalatine ganglion (SPG)
Number of subjects: 10
Study 26334339 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 89
Study 26334339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Number of subjects: 89